[{"orgOrder":0,"company":"Enleofen Bio Pte","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Enx108A","moa":"IL-11 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Enleofen Bio Pte","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enleofen Bio Pte \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"5","companyTruncated":"Enleofen Bio Pte \/ Boehringer Ingelheim GmbH"}]

Find Clinical Drug Pipeline Developments & Deals by Enleofen Bio Pte

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio.

                          Product Name : Enx108A

                          Product Type : Antibody

                          Upfront Cash : $1,000.0 million

                          September 01, 2020

                          Lead Product(s) : Enx108A

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : IND Enabling

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : $1,000.0 million

                          Deal Type : Partnership

                          blank